AstraZeneca (AZN) Tops Q2 EPS by 93c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
AstraZeneca (AZN) Appoints Michel Demare as Incoming Board Chair
July 29, 2022 5:57 AM EDTAstraZeneca (NASDAQ: AZN) today announced the appointment of Michel Demaré as the Chair-designate of the Board.
His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior independent Non-Executive Director.
As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the conclusion of the Companys Annual General Meeting in April 2023. Michels... More
